StockData
Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc. (ORGO) stock

ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/30
$0.77−0.02 (-2.23%)

Close on Nov 20, 2026Market cap $99.29MP/E –Yield –

Organogenesis free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Organogenesis's free cash flow for the twelve months ending Jun 30, 2026 was $20.84M. For fiscal 2025 it was -$24.46M, down 685.7% from the year before. The highest annual figure on record is $30.76M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$24.46M-685.7%
FY2024Dec 31, 2024$4.18M-36.3%
FY2023Dec 31, 2023$6.55M–
FY2022Dec 31, 2022-$9.04M-129.4%
FY2021Dec 31, 2021$30.76M–
FY2020Dec 31, 2020-$12.21M–
FY2019Dec 31, 2019-$39.51M–
FY2018Dec 31, 2018-$62.49M–
FY2017Dec 31, 2017-$5.92M–
FY2016Dec 31, 2016-$6.23M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$32.75M–
Q1 FY2026Mar 31, 2026$17.98M–
Q4 FY2025Dec 31, 2025$34.77M+358.9%
Q3 FY2025Sep 30, 2025$844.00K-86.2%
Q2 FY2025Jun 30, 2025-$36.51M-1377.5%
Q1 FY2025Mar 31, 2025-$23.56M–
Q4 FY2024Dec 31, 2024$7.58M+3.9%
Q3 FY2024Sep 30, 2024$6.13M-43.0%
Q2 FY2024Jun 30, 2024$2.86M+149.2%
Q1 FY2024Mar 31, 2024-$12.38M–
Q4 FY2023Dec 31, 2023$7.29M–
Q3 FY2023Sep 30, 2023$10.76M–
Q2 FY2023Jun 30, 2023$1.15M-71.5%
Q1 FY2023Mar 31, 2023-$12.64M–
Q4 FY2022Dec 31, 2022-$2.86M-122.5%
Q3 FY2022Sep 30, 2022-$4.95M-144.4%
Q2 FY2022Jun 30, 2022$4.03M-69.4%
Q1 FY2022Mar 31, 2022-$5.26M–
Q4 FY2021Dec 31, 2021$12.72M-28.5%
Q3 FY2021Sep 30, 2021$11.15M+269.1%
Q2 FY2021Jun 30, 2021$13.15M–
Q1 FY2021Mar 31, 2021-$6.26M–
Q4 FY2020Dec 31, 2020$17.80M–
Q3 FY2020Sep 30, 2020$3.02M–
Q2 FY2020Jun 30, 2020-$11.50M–
Q1 FY2020Mar 31, 2020-$21.53M–
Q4 FY2019Dec 31, 2019-$9.86M–
Q3 FY2019Sep 30, 2019-$6.73M–
Q2 FY2019Jun 30, 2019-$13.05M–
Q1 FY2019Mar 31, 2019-$9.88M–
Q4 FY2018Dec 31, 2018-$17.77M–
Q3 FY2018Sep 30, 2018-$23.93M–
Q2 FY2018Jun 30, 2018-$16.27M–
Q1 FY2018Mar 31, 2018-$4.52M–

More Organogenesis figures

See a number that looks wrong?